Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00345904
Status:
COMPLETED
Last Update Posted:
2016-09-28
First Post:
2006-06-28
Brief Title:
Study to Evaluate the Safety and Immunogenicity of Fluarix 20062007 in Adults Aged 18 Years or Above
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix Influsplit SSW 20062007 in People Aged 18 Years or Above
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vaccination is currently the most effective mean of controlling influenza and preventing its complications and mortality in persons at risk Because of the variable nature of influenza viruses the composition of influenza vaccines changes almost every year to target the 3 main circulating strains Each year the influenza vaccine formulation may thus be different and clinical studies are mandated to ensure that the immunogenicity and safety of the vaccine formulated from the three annual circulating strains are similar to what was observed during the previous years
This study is designed to test the immunogenicity and reactogenicity of the Fluarix vaccine containing the influenza strains recommended for the 2006-2007 season
This study is designed to test the immunogenicity and reactogenicity of the Fluarix vaccine containing the influenza strains recommended for the 2006-2007 season
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None